Thymic Mucosa-Associated Lymphoid Tissue Lymphoma
NCI Definition: A low-grade extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue that affects the thymus. It is characterized by the presence of centrocyte-like or monocytoid lymphocytes that surround reactive lymphoid follicles. There is infiltration of the thymic epithelium by lymphocytes and formation of lymphoepithelial lesions. It is associated with the presence of autoimmune disease, most frequently Sjogren syndrome. Patients are usually asymptomatic and the tumor is detected incidentally as a mediastinal mass on chest x-ray. A minority of patients present with dyspnea, hemoptysis, and chest pain. The prognosis is excellent. 
There is 1 clinical trial for thymic mucosa-associated lymphoid tissue lymphoma, of which 1 is open and 0 are completed or closed. Of the trial that contains thymic mucosa-associated lymphoid tissue lymphoma as an inclusion criterion, 1 is phase 1 (1 open).
Plamotamab is the most common intervention in thymic mucosa-associated lymphoid tissue lymphoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.